Shareholder Alert: The Ademi Firm investigates whether Adverum Biotechnologies, Inc. is obtaining a Fair Price for its Public Shareholders

Core Points - Adverum is under investigation for potential breaches of fiduciary duty and other legal violations related to its transaction with Eli Lilly [1] - The transaction offers Adverum shareholders $3.56 in cash and contingent value rights potentially worth up to $8.91 per share, totaling a maximum of $12.47 per share [2] - The contingent value rights include up to $1.78 per share contingent on U.S. approval of Ixo-vec within seven years and up to $7.13 per share if annual worldwide net sales exceed $1 billion within ten years [2] - The transaction agreement restricts competing offers for Adverum, imposing significant penalties for accepting alternative bids, raising concerns about the board's fiduciary duties [3] Company and Industry Insights - The Ademi Firm specializes in shareholder litigation concerning buyouts, mergers, and shareholder rights, indicating a focus on protecting investor interests in corporate transactions [4] - The investigation into Adverum reflects broader concerns in the industry regarding the fairness of transactions and the responsibilities of corporate boards to their shareholders [3][4]